Arshad M. Khanani, MD, MA, FASRS

The 18-month extension of the GATHER2 trial indicated continued benefit for patients receiving avacincaptad pegol, with efficacy gains increasing over time.

Advancements in drug durability and patient care are closing treatment gaps.